Abstract
In this study, we evaluated SEA-H61D, a staphylococcal enterotoxin A mutant without emetic activity, as an antitumor agent in vitro and in vivo. It showed that SEA-H61D could significantly inhibit the growth of many cancer cell lines in vitro at very low concentrations by activating human peripheral blood mononuclear cells (PBMCs). CD4+ and CD8+ T lymphocytes could be activated at a dose between 125 and 500 μg/kg. Systemic administration of SEA-H61D in vivo significantly inhibited tumor growth, with the treated group undergoing tumor necrosis and showing a strong infiltration of lymphocytes to the tumor area.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Breast Neoplasms / drug therapy
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / drug effects
-
CD8-Positive T-Lymphocytes / immunology
-
Carcinoma, Hepatocellular / drug therapy
-
Cell Division / drug effects*
-
Cell Line, Tumor
-
Colonic Neoplasms / drug therapy
-
DNA Primers
-
Enterotoxins / genetics*
-
Enterotoxins / pharmacology
-
Female
-
Humans
-
Interferon-gamma / metabolism
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / immunology
-
Lung Neoplasms / drug therapy
-
Melanoma / drug therapy
-
Mice
-
Mice, Inbred C57BL
-
Mutation
Substances
-
Antineoplastic Agents
-
DNA Primers
-
Enterotoxins
-
enterotoxin A, Staphylococcal
-
Interferon-gamma